9月12日，力生制药盘中上涨2.04%，截至10:34，报24.47元/股，成交7455.72万元，换手率1.23%，总市 值63.06亿元。 资金流向方面，主力资金净流入1105.95万元，特大单买入1040.27万元，占比13.95%，卖出206.54万 元，占比2.77%；大单买入1803.91万元，占比24.19%，卖出1531.69万元，占比20.54%。 分红方面，力生制药A股上市后累计派现12.61亿元。近三年，累计派现2.55亿元。 机构持仓方面，截止2025年6月30日，力生制药十大流通股东中，大成景恒混合A（090019）退出十大 流通股东之列。 责任编辑：小浪快报 资料显示，天津力生制药股份有限公司位于天津市西青经济技术开发区赛达北一道16号，成立日期1981 年6月17日，上市日期2010年4月23日，公司主营业务涉及从事化学药片剂、硬胶囊剂、滴丸剂、冻干粉 针剂、水针剂、原料药等产品的生产销售。主营业务收入构成为：片剂59.92%，针剂15.69%，丸剂 8.80%，胶囊8.75%，其他4.68%，颗粒剂2.16%。 力生制药所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块 ...

Core Viewpoint - The stock of Shuanglu Pharmaceutical has experienced fluctuations, with a recent decline of 2.04% and a total market capitalization of 7.89 billion yuan, indicating potential volatility in investor sentiment [1]. Financial Performance - For the first half of 2025, Shuanglu Pharmaceutical reported a revenue of 305 million yuan, a year-on-year decrease of 22.24%, while the net profit attributable to shareholders increased significantly by 309.08% to 121 million yuan [2]. - The company has distributed a total of 2.12 billion yuan in dividends since its A-share listing, with 277 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Shuanglu Pharmaceutical increased to 58,500, with an average of 14,564 circulating shares per person, a slight decrease of 1.33% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 8.69 million shares, an increase of 2.34 million shares from the previous period [3].

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].

Market Overview - The Shanghai Composite Index closed at 3615.72 points, up 0.17%, with a trading volume of 819.63 billion yuan [1] - The Shenzhen Component Index closed at 11203.03 points, down 0.77%, with a trading volume of 1024.65 billion yuan [1] - The ChiNext Index closed at 2367.68 points, down 1.62%, with a trading volume of 503.32 billion yuan [1] - The STAR 50 Index closed at 1058.57 points, down 1.11%, with a trading volume of 35.32 billion yuan [1] - The total trading volume of both markets was 1844.28 billion yuan, an increase of 41.11 billion yuan compared to the previous trading day [1] Sector Performance - Strong sectors included steel, oil and petrochemicals, media, food and beverage, banking, and textiles [3] - Active concepts included aquaculture, oil and gas services, dairy, heparin, film and television, and marine economy [3] - Weak sectors included electric equipment, computers, automobiles, defense and military, securities, telecommunications, machinery, and real estate [3] - The computer sector saw the largest net outflow of funds, amounting to 89.79 billion yuan [5] Fund Flow - The net outflow of main funds from the Shanghai and Shenzhen markets was 52.9 billion yuan [4] - The net outflow from the ChiNext was 21.25 billion yuan, while the Shanghai 300 index saw a net outflow of 12.33 billion yuan [5] - Only four sectors saw net inflows: media (10.72 billion yuan), social services (1.99 billion yuan), food and beverage (1.61 billion yuan), and retail (0.75 billion yuan) [5] Individual Stock Performance - A total of 1890 stocks experienced net inflows, with 41 stocks receiving over 1 billion yuan in net inflows [6] - The stock with the highest net inflow was Yingweike, with 867 million yuan [7] - Conversely, 3255 stocks faced net outflows, with 159 stocks seeing over 1 billion yuan in net outflows [8] - The stock with the highest net outflow was Ningde Times, with 1.293 billion yuan [9] Institutional Activity - Institutions had a net sell of approximately 72.4 million yuan, with 14 stocks seeing net purchases and 14 stocks seeing net sales [10] - The stock with the highest net purchase by institutions was Xizang Tianlu, with 126 million yuan [11]

Group 1 - The global exoskeleton robot market is entering a rapid growth phase, with a projected market size of $1.8 billion in 2024 and expected to exceed $12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 28% [1] - China's 14th Five-Year Plan includes exoskeletons as a key development area for high-end medical equipment, with several regions incorporating rehabilitation exoskeletons into insurance reimbursement, which is expected to accelerate commercialization [1] - The medical rehabilitation sector is seeing mature commercialization scenarios supported by policies, with a focus on three main directions: hospital policy support (innovative drugs and devices), expanding public demand (blood products, home medical devices, weight loss drug supply chain), and an upward trend in overseas market cycles (heparin, respiratory joint inspection) [1] Group 2 - The Medical ETF (159828) tracks the CSI Medical Index (code: 399989), which is compiled by the China Securities Index Co., selecting listed companies in the medical device, medical services, and pharmaceutical commercial sectors to reflect the overall performance of related securities [1] - The CSI Medical Index has strong industry representation, with the latest trading day showing an increase of 0.95%, serving as an important reference for investors looking to allocate in the healthcare industry [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Connect A (012634) and Guotai CSI Medical ETF Connect C (012635) [1]